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Edited by Hans-Dieter KlenkAbstract SARS-CoV is a newly identiﬁed coronavirus that
causes severe acute respiratory syndrome (SARS). Currently,
there is no eﬀective method available for prophylaxis and treat-
ment of SARS-CoV infections. In the present study, the inﬂuence
of small interfering RNA (siRNA) on SARS-CoV nucleocapsid
(N) protein expression was detected in cultured cells and mouse
muscles. Four siRNA expression cassettes driven by mouse U6
promoter targeting SARS-CoV N gene were prepared, and their
inhibitory eﬀects on expression of N and enhanced green ﬂuores-
cence protein (EGFP) fusion protein were observed. A candidate
siRNA was proved to down-regulate N and EGFP expression ac-
tively in a sequence-speciﬁc manner. The expression vector of
this siRNA was constructed and conﬁrmed to reduce N and
EGFP expression eﬃciently in both cultured cells and adult
mouse muscles. Our ﬁndings suggest that the siRNA should pro-
vide the basis for prophylaxis and therapy of SARS-CoV infec-
tion in human.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNA1. Introduction
Severe acute respiratory syndrome (SARS), an emerging
infectious disease of humans, appeared in China in November
2002 and spread to 30 countries in early 2003. The etiologic
agent of SARS was identiﬁed as a coronavirus (CoV) and se-
quence analysis reveals that the SARS-CoV is distinct from
all known human coronaviruses [1–3]. The two previously
identiﬁed human CoVs are associated only with mild upper
respiratory tract diseases, whereas the novel SARS-CoV ap-
pears to be the ﬁrst human coronavirus responsible for severe
disease in humans [4,5]. All CoVs encode a common set of
structural components consisting of a nucleocapsid protein
(N) and three integral membrane proteins, namely the spike
protein (S), the membrane protein (M), and the envelope pro-
tein (E) [6,7]. The S protein plays essential roles in mediating
receptor binding and internalization of the virus and is one*Corresponding author. Fax: +86 21 2507 0312.
E-mail address: qizt@smmu.edu.cn (Z.-T. Qi).
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are essential for virion assembly, and the N protein binds to
a deﬁned packaging signal on viral genome RNA, leading to
the formation of the helical nucleocapsid [6,7].
RNA interference (RNAi) is a process in which double-
stranded RNA (dsRNA) induces the posttranscriptional deg-
radation of homologous transcripts, and has been observed
in a variety of organisms including plants, fungi, insects, Dro-
sophila, and mammals [9–11]. It is believed to have evolved as a
host defense mechanism directed at transposable elements and
infectious viruses. Many studies have proved that siRNA can
signiﬁcantly suppress gene expression when exposed to mam-
malian cells in vitro [12–14]. Moreover, a number of groups
demonstrated eﬀective silencing of both endogenous gene and
transgene expression in vivo [15–18]. These ﬁndings raised
the possibility that RNAi might advance the ﬁeld of therapeu-
tic approaches for virus infection. In this study, we screened an
expression cassette-based siRNA that targets at the N sequence
of SARS-CoV, and it can signiﬁcantly suppress the expression
of SARS-CoV N protein in cultured cells in a sequence-speciﬁc
manner. Furthermore, the siRNA expression vector was con-
structed and proved to be eﬀective in silencing the expression
of SARS-CoV N protein in adult mouse muscles.2. Materials and methods
2.1. Construction of SARS-CoV N and EGFP fusion protein expression
plasmid
The 1266 base pair, none-stop codon fragment of SARS-CoV N
gene was synthesized according to the published sequence (GenBank
accession number: AY278554, the nucleoprotein coding region is from
nt 28105 to nt 29373 in the full length SARS-CoV genome) and used as
the template to amplify the DNA fragment for construction of N and
enhanced green ﬂuorescence protein (EGFP) fusion protein expression
plasmid. The forward primer was 5 0-GAATTCGCCACCATGTCT-
GATAATGGACCCCAATC-30; and the reverse primer was 5 0-
GGATCCATTGCCTGAGTTGAATCAGCAG-3 0 (the underlined
sequences were EcoRI and BamHI sites, respectively). Then the
EcoRI–BamHI fragment was transferred into pEGFP-N1 vector
(Clontech), yielding the recombinant pN-EGFP construct, in which
N gene was located upstream of EGFP. The inserted fragment was ver-
iﬁed by restriction endonucleases digestion and DNA sequencing.
2.2. Selection of the siRNA target sites and preparation of siRNA
expression cassettes
The siRNAs targeting SARS-CoV N sequence were selected based
on the following guidelines: (1) the 19–21 nucleotides that following
AA dinucleotides, (2) the sequence begins with G that preferringblished by Elsevier B.V. All rights reserved.
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GC, (4) the sequence does not contain a run of 4 or 5 As or Ts for
avoiding early termination of RNA polymerase III transcript and (5)
the sequence has no homology with any known human genes. The se-
lected siRNA target sites were shown in Table 1. The S1184 target site
is speciﬁc for SARS-CoV S gene, and muN388 target site is a mutant
sequence for N388, in which bi-nucleotides of the 6th site C and 7th
site G are reversed from N388. Both of the S1184 and muN388 were
served as controls for analysis of the speciﬁcity of the siRNA. PCR
based siRNA expression cassettes, containing U6 promoter, a 19–21-
nt sense strand of siRNA, a 9-nt loop, a 19–21-nt antisense strand of
siRNA, and a stretch of six deoxythymidines (poly(T)6), were ampli-
ﬁed by a two-step PCR described by Castanotto [19] and Gou [20]
(Fig. 1). The 5 0 primer mU6F 5 0-GAATTGGGTACCCGCTCTAG-
3 0, is complementary to 20 nt at the 5 0 end of the murine U6 promoter
and was used for all PCR procedures. In the ﬁrst round of PCR, theTable 1
The siRNA target sequences and the reverse primers for preparation of siRN
siRNA Sequence Reverse primer
N186 5 0-GGAGGAACTTAGATTCCCT-3 0 3 0 primer 1:5
3 0 primer 2:5
N388 5 0-GGCATCGTATGGGTTGCAACT-30 3 0 primer 1:5
3 0 primer 2:5
N587 5 0-GAAATTCAACTCCTGGCAG-3 0 3 0 primer 1:5
3 0 primer 2:5
N811 5 0-GTCACTCAAGCATTTGGGAGA-30 3 0 primer 1:5
3 0 primer 2:5
S1184 5 0-GACAAATAGCGCCAGGACA-3 0 3 0 primer 1:5
3 0 primer 2:5
muN388 5 0-GGCATGCTATGGGTTGCAACT-30 3 0 primer 1:5
3 0 primer 2:5
a30 primer 1 denotes the reverse primer for the ﬁrst round PCR, 3 0 primer 2
Fig. 1. Preparation of PCR-based siRNA expression cassettes. (A) Two-step
text, the PCR products consist of mouse U6 promoter, short hairpin DNA an
cassettes were prepared by two rounds of PCR. Lanes 1–4: PCR produc
respectively. Lane 5: PCR product of muN388 expression cassettes. Lane 6:
mouse U6 promoter.plasmid pSilence1.0-U6 containing mouse U6 promoter (Ambion)
was used as template, and the reverse primers contain the 9-nt loop
(5 0-TTCAAGAGA-3 0), a 19–21-nt antisense sequence of siRNA target
site and the complementary sequence to the last 14 nts of the mouse U6
promoter (5 0-GCCTTGTTTGGGCC-3 0). The PCR ampliﬁcation
using Pfu DNA Polymerase was carried out as follows: 94 C for
4 min; 94 C for 30 s, 58 C for 30 s, 72 C for 40 s, 30 cycles; 72 C
for 10 min. One microliter of the ﬁrst PCR product was re-ampliﬁed
using the mixture of Taq and Pfu DNA Polymerase. The ampliﬁcation
conditions and forward primer were the same as those in the ﬁrst
round PCR, while the reverse primers contain poly(A)6, a 19–21-nt
sense strand of siRNA target site, and a complementary sequence to
the 9-nt loop. In addition, the mouse U6 promoter was ampliﬁed as
a control for siRNA screening. The second round PCR products were
puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen). All the reverse
primers were listed in Table 1.A expression cassettes
sequencea
0-TCTCTTGAAAGGGAATCTAAGTTCCTCCGGCCCAAACAAGGC-30
0-AAAAAAGGAGGAACTTAGATTCCCTTCTCTTGAAAGG-3 0
0-TCTCTTGAAAGTTGCAACCATACGATGCGGCCCAAACA AGGC-30
0-AAAAAAGGCATCGTATGGGTTGCAACTTCTCTTGAAAGTTG-30
0-TCTCTTGAACTGCCAGGAGTTGAATTTCGGCCCAAACAAGGC-30
0-AAAAAAGAAATTCAACTCCTGGCAGTCTCTTGAACTG-3 0
0-TCTCTTGAATCTCCCAAATGCTTGAGTGACGGCCCAAACAAGGC-3 0
0-AAAAAAGTCACTCAAGCATTTGGGAGATCTCTTGAATCT-30
0-TCTCTTGAATGTCCTGGCGCTATTTGTCGGCCCAAACAAGGC-30
0-AAAAAAGACAAATAGCGCCAGGACATCTCTTGAATGT-3 0
0-TCTCTTGAAAGTTGCAACCATAGCATGCGGCCCAAACA AGGC-30
0-AAAAAAGGCATGCTATGGGTTGCAACTTCTCTTGAAAGTTG-30
denotes the reverse primer for the second round PCR.
PCR procedure for the siRNA expression cassettes was described in the
d terminator sequence, six thymidines (T6). (B) The siRNA expression
ts of siRNA expression cassettes of N186, N388, N587 and N811,
PCR product of S1184 expression cassettes. Lane 7: PCR product of
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293T, CHO and Vero E6 cells were cultured in Dulbeccos modiﬁed
Eagles medium supplemented with 10% fetal bovine serum (FBS),
1 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin.
Twenty-four hours before transfection, 60–80% conﬂuent cells were
trypsinized, and 1 · 105 cells were plated into a 24-well format in
500 ll of fresh culture medium without antibiotics. The plasmid pN-
EGFP (0.4 lg) was co-transfected with the siRNA expression cassettes
(0.4 lg) using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturers instructions. At various time points, the cells were exam-
ined for the expression of EGFP with a ﬂuorescence microscope
(Olympus) and the expression of SARS-CoV N protein was detected
by Western blot and real-time PCR analyses.
2.4. Construction of siRNA expression vector
After observation of the inhibitory eﬀects of the siRNA expression
cassettes on the expression of SARS-CoV N and EGFP protein, the
most active siRNA expression cassette that targets 388–408-nt of
SARS-CoV N sequence was inserted into the pMD-18T vector (Ta-
KaRa) using TA-cloning technique, and the correct sequence was ver-
iﬁed by DNA sequencing. The resulting siRNA expression plasmid
pU6-shN388 was used for the further study.2.5. Eﬀect of siRNA expression vector on expression of SARS-CoV N
protein in cultured cells
For the sequence speciﬁcity analysis of the siRNA, a plasmid pCI-
HBc was used as an unrelated viral gene expression control, which
was constructed by inserting of hepatitis B virus core antigen (HBcAg)
DNA sequence into a eukaryotic expression vector pCI-neo (Prome-
ga). 293T cells plated in 35 mm dishes were co-transfected respectively
with plasmids (1) 0.3 lg pN-EGFP, 0.3 lg pCI-HBc and 0.6 lg
pUC18, (2) 0.3 lg pN-EGFP, 0.3 lg pCI-HBc, 0.3 lg pU6-shN388
and 0.3 lg pUC18, or (3) 0.3 lg pN-EGFP, 0.3 lg pCI-HBc and
0.6 lg pU6-shN388. At 48 h post-transfection, the cells were harvested
for Western blot analysis.
2.6. Eﬀect of siRNA on expression of SARS-CoV N protein in murine
skeletal muscles
Plasmids pN-EGFP, pU6-shN388 and pUC18 were puriﬁed using
QIAﬁltere Plasmid Mega kit (Qiagen) and mixed respectively with
3.4% polyvinyl pyrrolidone (PVP, MW 40 000, Sigma) in 0.01 M
PBS to a ﬁnal concentration of 2 g/l. These plasmids were later used
for muscle injection of mice. Six-week old female BALB/c mice (Xi-
per-Bikai Experimental Animal Co., LTD, Shanghai) were randomly
divided into two groups (four mice in each group). The experimental
group were injected with 15 ll pN-EGFP and 45 ll pU6-shN388 at
both sides of tibialis anterior muscles, and the control group received
15 ll pN-EGFP and 45 ll pUC18. At day 4, 8, 12 and 16 post-injec-
tion, one mouse per group was sacriﬁced, and the tibialis anterior mus-
cles were isolated for N and EGFP expression analyses.
2.7. Reverse transcription and real-time PCR
Total RNA from the transfected cells was extracted using Trizol re-
agent (GIBCO) according to the manufacturers instruction and then
treated with RNase-free DNase 1 (Promega). To make sure that no
plasmid pN-EGFP derived DNA presented in the total RNA, 0.1 lg
of each total RNA was checked by PCR using the 5 0 primer
(5 0-CCTCGCGCTATTGC-3 0) and 3 0 primer (5 0-GATGCCTCAG
CAGCAG-3 0) prior to reverse transcription, and no a 111-bp fragment
corresponding to the nt 657–766 of SARS-CoV N gene was obtained.
One microgramme total RNA was subjected to reverse transcription
reaction with 5 U AMV reverse transcriptase (TaKaRa) and 2.5 pmol
oligo(dT)18 primer in 25 ll reaction mixture at 42 C for 40 min. The
RT product was then inactivated by heating at 99 C for 5 min and
subjected to real-time PCR analysis using SYBR Premix Ex Taqe sys-
tem (TaKaRa). For real-time PCR, 3 ll RT product was ampliﬁed in a
20 ll reaction volume containing 5 pmol of 5 0 primer and 3 0 primer,
and 10 ll SYBR Premix Ex Taqe 2· buﬀer (including SYBR green
I reagent, Taq DNA polymerase, and dNTP). The primers for
SARS-CoV N are the same as those used in PCR for total RNA. Fol-
lowing a denaturation step at 95 C for 10 s, the ampliﬁcation reaction
was performed 40 cycles at 95 C for 5 s, 60 C for 20 s in a real-time
quantitative Lightcyclere system (Roche). Each sample was run intriplicate. Six serially 10-fold diluted samples of EcoRI–BamHI frag-
ment of N sequence (varied from 107 to 102 copies in each reaction)
were used to create standard curve for the quantitation of SARS N
cDNA concentration in RT product. For analysis of SARS-CoV N
mRNA in mouse skeletal muscles, the tibialis anterior muscles were
freeze–thawed and homogenized, and the cellular RNA was extracted
as described above.
2.8. Western blot
Cells were lyzed using lysis buﬀer (1% Triton X-100, 2 mM EDTA,
50 Mm Tris–HCl, pH 7.4, 200 lg/ml leupeptin, and 1 mM phenylmeth-
ylsulfonyl ﬂuoride), and the cell lysate was separated by sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis and electrophoretically
transferred to nitrocellulose membrane. The primary antibodies used
for detection of speciﬁc proteins were as follows: anti-SARS-CoV N
positive sera from convalescent SARS patients (1:200 dilution), anti-
HBcAg positive sera from acute hepatitis B patients (1:500 dilution)
and anti-b-actin monoclonal antibody (SantaCruz, 1:1000 dilution).
The secondary antibody detection was performed using alkaline phos-
phatase-conjugated goat anti-human IgG, or horseradish peroxidase-
conjugated goat anti-mouse IgG, and immunoreactive bands were
visualized with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-
phosphate (NBT/BCIP; Pierce), or DAB and H2O2. For detection of
SARS-CoV N protein in mouse skeletal muscles, the isolated tibialis
anterior muscles were freeze–thawed, homogenized, and the extracted
protein was analyzed by the procedure similar to that described above.3. Results
3.1. Preparation of mouse U6 promoter-derived siRNA
expression cassettes
For constructing the siRNA expression cassettes, a proce-
dure consisting of two rounds of PCR was used as described
by Castanotto [19] and Gou [20], and the resulting PCR prod-
ucts include the mouse U6 promoter, sense sequence, loop,
antisense sequence, and followed by the Pol III terminator se-
quence poly(T)6 (Fig. 1A). Using this method, six siRNA
expression cassettes were prepared with the correct predicted
molecular weights (Fig. 1B).
3.2. Eﬃcient inhibition of SARS-CoV N-EGFP expression by
siRNA expression cassettes
The plasmid pN-EGFP was transfected into 293T, CHO and
Vero E6 cells either alone or along with siRNA expression cas-
settes, respectively. At various time points post-transfection,
the eﬀect of siRNA on EGFP expression was monitored by
ﬂuorescence microscope. The results showed that all four siR-
NA expression cassettes targeting N gene could inhibit the
expression of EGFP to some extent compared with that in cells
transfected with plasmid pN-EGFP alone, especially for N388
expression cassette. The N388 expression cassette targeting nt
388–407 of N sequence was most eﬀective, and only very weak
ﬂuorescence was observed at 48–72 h post-transfection. No
signiﬁcant inhibition of EGFP expression was observed at
any time in cells that co-transfected with the control constructs
(the mouse U6 promoter or S1184 siRNA expression cassette).
Given that the inhibition of N388 expression cassette on the
EGFP expression, its mutant version (muN388) with two
nucleotides reversed was prepared. The muN388 gave little
inﬂuence on EGFP expression.
Western blot and semi-quantitative real-time PCR were car-
ried out for determination of the inhibitory eﬀect of the siRNA
on SARS-CoV N gene expression. Western blot demonstrated
that the inhibition of N gene shRNA on the N protein was
similar as that on EGFP expression. The suppressive eﬀect
Fig. 2. Inhibition of SARS-CoV N protein expression by siRNA expression cassettes. The 293T cells were co-transfected with N-EGFP expression
plasmid and various PCR products. The SARS-CoV N protein expression was measured. (A) N protein expression was detected by Western blot at
48 h post-transfection. The upper panel shows N protein expression (lane 1 shows N expression in cells transfected with pN-EGFP alone, other lanes
show that in cells co-transfected with pN-EGFP and various PCR products, U6P denotes PCR product of mouse U6 promoter only). The lower
panel shows b-actin expression (as an endogenous control). (B) At 48 h post-transfection, the total RNA was isolated and subjected to reverse
transcription and real-time PCR analysis. The mRNA levels of cells transfected with plasmid pN-EGFP along with various PCR products were
quantitated relative to that in the cells transfected with plasmid pN-EGFP alone.
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structs and mutant muN388 had little eﬀect (Fig. 2A). The
real-time PCR assay also showed that the four siRNA expres-
sion cassettes could down-regulate the mRNA transcription of
N gene. The three control constructs co-transfected with the
pN-EGFP only had marginal eﬀect on the mRNA of N gene
(Fig. 2B). Therefore, the N388 siRNA was selected for further
studies.
3.3. Silencing of N-EGFP by siRNA expression vector in
cultured cells
The N388 siRNA expression vector was constructed by
inserting the expression cassette into the vector pMD18-T
(Fig. 3A). The recombinant vector was co-transfected into cul-
tured cells with the N-EGFP expression plasmid. The hepatitis
B virus core antigen expression plasmid was adopted as an
exogenous gene control in this assay. As shown in Fig. 3B
and C, the siRNA expression vector inhibits N and EGFP
expression in 293 cells in a dose-dependent manner. With
0.6 lg pU6-shN388 administered, N and EGFP expression
were signiﬁcantly suppressed, while HBcAg expression was
not inﬂuenced.
3.4. Silencing of N-EGFP by siRNA expression vector in mouse
muscles
A mouse model expressing N-EGFP fusion protein in skele-
tal muscles was used to test the potential anit-SARS-CoVactivity of the siRNA in vivo. When intramuscularly co-in-
jected the N-EGFP expression plasmid and N388 siRNA
expression plasmid pU6-shN388 to mice, we found that the
plasmid pU6-shN38 could reduce the expression of EGFP
and N protein signiﬁcantly, and this inhibitory eﬀect lasted
16 days of the entire observation period (Fig. 4). Real-time
PCR analysis showed that the mRNA level of SARS-CoV N
in mouse muscles was reduced to 19%, 17%, 21% and 23%,
relative to that co-injected with pN-EGFP and control plasmid
pUC18 at day 4, 8, 12 and 16 after siRNA delivery,
respectively.4. Discussion
Small interfering RNAs (siRNAs), mediators of RNAi, are
short (21–26 nt), dsRNA duplexes that inhibit gene expression
by inducing sequence-speciﬁc degradation of homologous
RNA, which may stand for a new promising method for pro-
tection against viral infection [12–14,16,18]. Several methods
have been introduced for siRNA preparation, such as chemical
synthesis, T7 RNA polymerase directed in vitro transcription,
and short hairpin RNAs (shRNAs) expressed from DNA vec-
tors. A PCR-based shRNA expression cassette may represent
one of the most time- and labor-saving methods, especially
for the identiﬁcation of speciﬁc and eﬃcient target sites
[19,20]. In addition, PCR products can be easily inserted into
Fig. 3. Inhibition of SARS-CoV N protein expression by siRNA expression vector. The N388 siRNA expression vector was constructed and its
inﬂuence on the N-EGFP expression was detected in cultured 293T cells. (A) The PCR product of N388 siRNA expression cassette was inserted into
the vector pMD-18T, and the resulting plasmid was used as siRNA expression vector. (B) 293T cells were co-transfected with plasmid pN-EGFP and
N388 siRNA expression vector, along with HBcAg expression plasmid as an unrelated control. The images show the EGFP expression at 48 h post-
transfection. The left panel shows the cells under a bright ﬁeld. (C) The expression of N protein and HBcAg were detected by Western blot at 48 h
post-transfection. Lane 1: 293T cells transfected with 0.3 lg pN-EGFP, 0.3 lg pCI-HBc and 0.6 lg pUC18. Lane 2: 293T cells transfected with 0.3 lg
pN-EGFP, 0.3 lg pCI-HBc and 0.3 lg pU6-shN388. Lane 3: 293T cells transfected with 0.3 lg pN-EGFP, 0.3 lg pCI-HBc and 0.6 lg pU6-shN388.
In ﬂuorescence and Western blot analysis, plasmid pUC18 was used to standardize the plasmid dosage for transfection. The experiment was repeated
three times, and similar results were obtained.
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tags are present in the primers, directional cloning into plasmid
vectors is also feasible.
The N protein of SARS-CoV is a key protein for the forma-
tion of the helical nucleocapsid in the cytoplasm, and is more
conserved than other structural protein, which makes it an
ideal target for RNA interference [2,3]. In this study, four siR-
NA candidate sites targeting SARS-CoV N sequence were se-
lected, and mouse U6 promoter regulated siRNA expression
cassettes were constructed. All four candidate siRNAs gave
some reduction of EGFP expression in cultured cells, and
N388 showed the most signiﬁcant eﬀect. Western blot demon-
strated the similar inhibitory eﬀect on N protein and EGFP,
and the semi-quantitative PCR conﬁrmed that N388 down-regulated mRNA of N gene more eﬃciently than other three
siRNAs did. For gene intervention, sequence speciﬁcity is very
important for its practical application. It is know that, in
mammalian cells, dsRNA 30 base pairs or longer can trigger
interferon responses that are intrinsically sequence-nonspeciﬁc
[21–23]. In our observation, the control PCR products, includ-
ing the U6 promoter, SARS-CoV S-targeted siRNA expres-
sion construct, have little inﬂuence on the N-EGFP
expression. More importantly, the bi-nucleotide reversed mu-
tant of N388 siRNA had no inhibitory activity for N-EGFP
expression. These results indicate that the inhibition of N-
EGFP expression by siRNAs is sequence-speciﬁc, requiring
homology between the siRNAs and gene targets, and is not
the consequence of interferon responses induced by dsRNA.
Fig. 4. Silencing of N-EGFP expression by siRNA in mouse muscles. Mice were injected with N-EGFP expression plasmid and the siRNA
expression vector in both tibialis anterior muscle. The N and EGFP expression was detected at day 4, 8, 12 and 16 post-injection. (A) The muscles
were isolated and frost slices were prepared, and EGFP expression was visualized under ﬂuorescence microscope. The upper panel shows EGFP
expression in mice injected with plasmid pN-EGFP along with siRNA expression vector at various time post-injection. The lower panel shows EGFP
expression in mice injected with plasmid pN-EGFP along with pUC18. (B) The muscles were isolated and N protein expression was detected by
Western blot at diﬀerent times. The upper panel indicates N protein expression in mouse muscles injected with plasmid pN-EGFP along with: (1)
pUC18 or (2) siRNA expression vector. The lower panel shows b-actin expression as a loading control. The plasmid pUC18 used was to standardize
the plasmid dosage for gene delivery in vivo. This ﬁgure shows the results of one representative experiment of two.
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inserting the PCR product into the T vector for further obser-
vation. In cultured cells, this plasmid could signiﬁcantly sup-
press N-EGFP expression in a dose-dependent manner, while
the expression of another viral protein, HBcAg, did not
change. As the expression of both N-EGFP and HBcAg are
driven by the same transcriptional control element (CMV
immediate/early promoter/enhancer) and that down-regulation
of viral RNA by cytokines is not sequence-speciﬁc, our results
suggest that the inhibitory eﬀect of siRNA or the SARS-CoV
N expression is not due to IFN response, but sequence-depen-
dent siRNA mechanism. To determine the potential biological
activities of siRNA in vivo, we established a mouse model
expressing N-EGFP in skeletal muscles. Muscle cells are excel-
lent for exogenous gene expression, for example, direct intra-
muscular DNA vaccine injection could lead to antigen
expression in muscle cells and induction of systemic immune
responses in hosts [24]. Analysis on protein and mRNA levels
showed that just as in cultured cells, the siRNAs could down-
regulate N and EGFP expression in mouse muscles, and their
eﬀects lasted the entire observation period. Though Lower
dose of siRNA develop less suppression activities on N and
EGFP expression, they still behave signiﬁcant inhibition.
When 0.4 lg, instead of 0.6 lg pU6-shN388 was administered,the mRNA of N gene was reduced to 28%, 24%, 31%, and 36%
at diﬀerent time points, respectively (data not shown).
Although we have not evaluated the activities of the siRNA
in respiratory tract, of the relevant target for SARS-CoV infec-
tion, the siRNA seems to be functional for silencing N protein
expression in vivo based on the data from mouse muscles and
the cultured cells, especially from Vero E6 cells, which is sup-
portive for SARS-CoV replication. The siRNAs are promising
for the development of antiviral agents for human use, espe-
cially when combining several siRNAs speciﬁc for diﬀerent
gene regions, and delivering with an appropriate carrier, such
as cationic polymers [25] or virus vectors, or with proper mod-
iﬁcation, such as linkage with cholesterol [26]. For the charac-
terization of SARS-CoV infection, the recombinant vaccinia
virus vector may be an attractive alternative for siRNA deliv-
ery. Recently, the siRNAs targeting the polymerase and S se-
quence were reported to silence gene expression and inhibit
SARS-CoV replication in mammalian cells eﬃciently [27–31].
Together with our data, it is considerable that siRNA may
be possible for developing anti-SARS agents.
In summary, we screened some siRNA candidates targeting
SARS-CoV N gene based on the siRNA expression cassettes,
and identiﬁed a siRNA N388, that could eﬃciently and specif-
ically inhibit the expression of SARS-CoV N protein in human
2410 P. Zhao et al. / FEBS Letters 579 (2005) 2404–2410293T cells and monkey Vero E6 cells. The inhibitory activity
and durable eﬀects of siRNA N388 on N expression were fur-
ther conﬁrmed in mouse muscles. Our present data suggest
that siRNA should be of potential values in prophylaxis and
treatment of SARS-CoV infection in humans.
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